Proceedings of the Food and Drug Administration public workshop on pathogen reduction technologies for blood safety 2018 (Commentary, p. 3026)

Transfusion. 2019 Sep;59(9):3002-3025. doi: 10.1111/trf.15344. Epub 2019 May 29.

¹ US Food and Drug Administration, Center for Biologics Evaluation and Research, Office of Blood Research and Review, Silver Spring, Maryland.
² National Heart Lung and Blood Institute, Bethesda, Maryland, USA.
³ Vitalant Research Institute, San Francisco, California.
⁴ Blood Bank, Yale-New Haven Hospital, New Haven, Connecticut.
⁵ Department of Pathology and Laboratory Medicine, Yale School of Medicine, New Haven, Connecticut.
⁶ Department of Pathology, Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire.
⁷ Department of Transfusion Medicine, NIH Clinical Center, Bethesda, Maryland.
⁸ Blood Components, American Red Cross, Rockville, Maryland.
⁹ Department of Lab Medicine and Pathology, University of Minnesota Medical Center, Minneapolis, Minnesota.
¹⁰ Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, Colorado.
¹¹ Cerus Corporation, Concord, California.
¹² R&D, TerumoBCT, Inc., Lakewood, Colorado.
¹³ Hoxworth Blood Center, University of Cincinnati Health, Cincinnati, Ohio.
¹⁴ The Robertson Trust Laboratory for Electronic Sterilisation Technologies (ROLEST), University of Strathclyde, Glasgow, Scotland.
¹⁵ Department of Hematology, Center for Biologics Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland.
¹⁶ U.S. Army Institute of Surgical Research, San Antonio, Texas.
¹⁷ Blood Bank, Johns Hopkins Hospital, Baltimore, Maryland.

No abstract available

Publication types